Reference-Standard Material Qualification - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Reference-Standard Material Qualification
The author reviews the types of reference-standard materials used in drug-product manufacturing, discusses current regulatory requirements, and outlines a reference-standard qualification program.

Pharmaceutical Technology
Volume 33, Issue 4, pp. 66-73

Reference standard program

Compendial. The use of compendial reference standards is preferred for a reference-standard program. Regulatory agencies will accept reference-standard materials from a pharmacopeial source and NIST without further qualification (1). NIST provides a certificate of analysis (CoA) that includes purity information and an expiration date. USP, however, labels its reference standards (assay reference standards to the nearest 0.1% and impurity reference standards to the nearest percent). In addition, USP reference standards are considered suitable for use up to one year after a new lot is released.

Wherever possible, therefore, compendial methods should be used to qualify reference standards. If the reference-standard program requires tests that are not captured in compendial methods (as is the case with organic impurities), then analytical test procedures must be developed and qualified. This can be an expensive process and may delay the process of stability or clinical programs.

Noncompendial. Applicants that use proprietary materials will find that primary standards are not typically available through compendial sources. As a result, noncompendial (secondary) reference standards require characterization and, thus, reference-standard development and qualification programs need to be implemented. Materials can be developed or purchased from chemical-supply companies for use as in-house secondary reference standards even when compendial reference standards are available. In such instances, the secondary reference standard should be qualified against the compendial reference standard.

Identification of impurities. Actual and potential degradation products should be isolated and identified during development of the reference standard. Typically, organic impurities are identified and confirmed using liquid chromatography–mass spectrometry (LG–MS); nuclear magnetic resonance (NMR) and inductively coupled plasma/mass spectrometry (ICP–MS) are used for inorganic impurities; and gas chromatography/mass spectrometry (LC–MS) is used for residual solvents.

It should also be determined whether enantiomeric or polymorphic forms exist. Each of these factors must be considered in the development of a comprehensive reference-standard material program. Qualification of a secondary source reference-standard material begins with obtaining a CoA, the synthesis pathway (if available), and a list of methods used in product manufacturing. This information can help analysts determine essential parameters for qualification. The identity of the material should be confirmed with a "fingerprinting" technique such as fourier transform infrared spectroscopy (FTIR) to a library source or by elemental analysis to confirm the molecular formula. Once identity has been established and confirmed, the quality of the material must be ascertained. Elemental analysis, titration, GC, or LC can be used for purity determination. Based on the results, the material may require further purification by distillation or recrystallization. Additional testing may be required to identify and quantify known or potential impurities that may have been overlooked during the manufacturer's assessment of the material.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here